Thursday, July 9, 2026

Patent intelligence · US

US 10413541

Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders

granted A61KA61K31/343A61K31/496
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 13
Applicant portfolio 26
Patent details — US 10413541
Jurisdiction
US
Status
granted
Grant date
Sep 17, 2019
Expiration
Sep 12, 2039
Claims
20
CPC classes
A61K, A61K31/343, A61K31/496
View on Google Patents ↗

Quick answer

US 10413541 (Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders) is held by Lixte Biotechnology, Inc.. Status: granted. Granted Sep 17, 2019. Expires Sep 12, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K31/343, A61K31/496

More from Lixte Biotechnology, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12343342

    Methods for treating soft tissue sarcoma

    Lixte Biotechnology, Inc. · Expires Jun 26, 2045

    granted
  2. US 11931354

    Formulations of oxabicycloheptanes and oxabicycloheptenes

    Lixte Biotechnology, Inc. · Expires Mar 14, 2044

    granted
  3. US 11866444

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Expires Jan 4, 2044

    granted
  4. US 11236102

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Expires Jan 27, 2042

    granted
  5. US 10668062

    Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes

    Lixte Biotechnology, Inc. · Expires May 28, 2040

    granted
  6. US 10618908

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Expires Apr 9, 2040

    granted
  7. US 10532050

    Formulations of oxabicycloheptanes and oxabicycloheptenes

    Lixte Biotechnology, Inc. · Expires Jan 9, 2040

    granted
  8. US 10434100

    Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes

    Lixte Biotechnology, Inc. · Expires Oct 3, 2039

    granted

Frequently asked questions

What is US patent 10413541?

US 10413541 (Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders) is held by Lixte Biotechnology, Inc.. Status: granted. Granted Sep 17, 2019. Expires Sep 12, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10413541?

Lixte Biotechnology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.

When does US 10413541 expire?

Our index shows an expiration date of Sep 12, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.